13F Filings History of Fan Yu
- Latest 13F filing
- Q1 2026 - 18 May 2026
- Latest reported 13F value
- $97,016,174
- Largest 13F holdings
-
KMTS ALMS CBLL IVA WHWK CATX PMN ABTC
- Form 13F summary
-
- Fan Yu Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Fan Yu reported 8 equity holdings with a total reported market value of $97,016,174 for Q1 2026. Top reported holdings included KMTS, ALMS, CBLL, IVA, and WHWK.
- Manager signature
- Fan Yu - Self
- Manager location
- Central, Hong Kong
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Fan Yu with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
List of Other Managers Reporting for Fan Yu:
| Name | Holdings Value | Location | File Number |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | $100,656,896 | New York, NY | 028-20834 |
| ABG Innovation Capital Partners III GP Ltd | $0 | Central, Hong Kong, Hong Kong | 028-20837 |
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q1 2026
Latest value
$97,016,174
Quarter delta
+$4,743,303
Accepted
15 May 2026, 20:49
Rows shown
1-23 of 23
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 8 | $97,016,174 | +$8,873,793 | -$281,389 | +$8,592,404 | KMTS, ALMS, CBLL, IVA, WHWK | 13F-HR | 15 May 2026, 20:49 |
| Q4 2025 | 5 | $92,272,871 | +$6,975,000 | -$17,625,536 | -$10,650,536 | KMTS, CBLL, ALMS, IVA, WHWK | 13F-HR | 17 Feb 2026, 19:30 |
| Q3 2025 | 4 | $76,864,104 | $0 | -$3,757,440 | -$3,757,440 | KMTS, CBLL, WHWK, ALMS | 13F-HR | 14 Nov 2025, 16:32 |
| Q2 2025 | 5 | $73,186,158 | +$2,452,956 | -$4,707,896 | -$2,254,940 | KMTS, CBLL, WHWK, CRGX, ALMS | 13F-HR | 14 Aug 2025, 16:36 |
| Q1 2025 | 9 | $97,313,288 | +$60,564,973 | $0 | +$60,564,973 | KMTS, CBLL, ALMS, CGON, CRGX | 13F-HR | 15 May 2025, 11:16 |
| Q4 2024 | 7 | $51,953,198 | +$31,630,588 | $0 | +$31,630,588 | CBLL, CRGX, ALMS, CSTL, SGMT | 13F-HR | 14 Feb 2025, 09:41 |
| Q3 2024 | 6 | $32,481,259 | $0 | -$53,789,964 | -$53,789,964 | CRGX, ALMS, CGON, CSTL, PYXS | 13F-HR | 14 Nov 2024, 07:30 |
| Q2 2024 | 6 | $76,530,244 | +$76,105,261 | -$71,930,309 | +$4,174,952 | CGON, CRGX, ALMS, CSTL, PYXS | 13F-HR | 14 Aug 2024, 08:01 |
| Q1 2024 | 5 | $72,535,510 | +$71,930,309 | -$19,518,874 | +$52,411,435 | PRE, AGLE, SONX, SGMT, PYXS | 13F-HR | 15 May 2024, 07:00 |
| Q4 2023 | 4 | $19,953,589 | +$19,518,874 | -$768,580 | +$18,750,294 | CRGX, CSTL, SGMT, PYXS | 13F-HR | 14 Feb 2024, 07:26 |
| Q3 2023 | 5 | $1,409,764 | +$641,184 | -$1,999,817 | -$1,358,633 | SGMT, SONX, AGLE, PYXS, PRE | 13F-HR | 14 Nov 2023, 15:44 |
| Q2 2023 | 5 | $1,274,878 | $0 | $0 | $0 | SONX, CSTL, APGN, AGLE, PRE | 13F-HR | 14 Aug 2023, 16:09 |
| Q1 2023 | 5 | $1,815,889 | $0 | -$5,058,117 | -$5,058,117 | SONX, CSTL, APGN, AGLE, PRE | 13F-HR | 15 May 2023, 11:20 |
| Q4 2022 | 6 | $7,467,955 | $0 | $0 | $0 | ABGI, SONX, CSTL, APGN, AGLE | 13F-HR | 14 Feb 2023, 10:23 |
| Q3 2022 | 6 | $7,340,000 | +$1,085,000 | $0 | +$1,085,000 | ABGI, APGN, SONX, CSTL, PRE | 13F-HR | 14 Nov 2022, 07:41 |
| Q2 2022 | 5 | $6,465,000 | +$553,000 | -$22,000 | +$531,000 | ABGI, SONX, CSTL, PRE, AGLE | 13F-HR | 15 Aug 2022, 09:40 |
| Q1 2022 | 4 | $7,395,000 | $0 | $0 | $0 | ABGI, SONX, AGLE, DIFFUSION PHARMACEUTICALS IN | 13F-HR | 16 May 2022, 06:54 |
| Q4 2021 | 4 | $8,618,000 | +$3,156,000 | $0 | +$3,156,000 | ABGI, SONX, AGLE, DIFFUSION PHARMACEUTICALS IN | 13F-HR | 14 Feb 2022, 07:41 |
| Q3 2021 | 3 | $5,820,000 | $0 | -$3,090,000 | -$3,090,000 | ABGI, AGLE, DIFFUSION PHARMACEUTICALS IN | 13F-HR | 15 Nov 2021, 07:12 |
| Q2 2021 | 4 | $8,849,000 | $0 | -$17,214,451 | -$17,214,451 | ABGI, AVIR, AGLE, DIFFUSION PHARMACEUTICALS IN | Restatement | 17 Sep 2021, 15:08 |
| Q1 2021 | 5 | $38,313,000 | +$4,958,000 | $0 | +$4,958,000 | AVIR, LUNG, ABGI, AGLE, DIFFUSION PHARMACEUTICALS IN | Restatement | 17 Sep 2021, 15:08 |
| Q4 2020 | 1 | $0 | $0 | $0 | $0 | New Holdings | 17 May 2021, 07:29 | |
| Q4 2020 | 3 | $13,487,000 | $0 | $0 | $0 | AVIR, AGLE, DIFFUSION PHARMACEUTICALS IN | 13F-HR | 16 Feb 2021, 07:17 |